[company_age]16.0[/company_age][employees]11-50 employees[/employees][funding]Series B[/funding][description]Eyevensys is a clinical-stage biotechnology company specializing in developing innovative gene therapy treatments for ophthalmic diseases. Their proprietary EyeCET platform utilizes electroporation to deliver plasmids encoding therapeutic proteins directly into the ciliary muscle of the eye. This approach enables sustained intraocular production of therapeutic proteins, offering a safe, non-viral, and convenient treatment option for patients with debilitating eye diseases. Eyevensys' lead product, EYS606, is a potential new treatment for non-infectious uveitis, the 4th leading cause of blindness worldwide. EYS606 has received orphan drug designation from the EMA and is currently in Phase I/II clinical trials. Eyevensys is headquartered in Paris, France, with additional locations in Cambridge, Massachusetts, and Fort Worth, Texas.[/description][ps]Gene therapy treatments for ophthalmic diseases[/ps]